For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

GLP-1 / Metabolic

Retatrutide

Also known as: Retatrutide (LY3437943 — GLP-1/GIP/Glucagon triple agonist)

Retatrutide (Eli Lilly code LY3437943) is an investigational triple-receptor agonist simultaneously targeting GLP-1, GIP, and glucagon receptors. It is research-only and NOT FDA-approved as of April 2026; the Phase 3 TRIUMPH program is ongoing with anticipated NDA filing in 2026. Published Phase 2 data showed roughly 24% mean body weight loss at 48 weeks on 12 mg weekly (Jastreboff, NEJM 2023).

Where to buy · live market data

Who's worth your money for Retatrutide

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (95) of 7 scored sellers

$1.83/mg

$110 · 60mg · 99.5% purity

Best value

Lowest $/mg among scored sellers

$1.00/mg

$10.00 · 10mg · 99.8% purity

Most tested

14 independent COAs on file

$8.67/mg

$130 · 15mg · 99.9% purity

Average price

$7.06/mg

Sellers

82

45-day trend

+3.5%

72 of 82 sellers have a current price· 65 stale hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch Retatrutide

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About Retatrutide

CAS

2381089-83-2

Molecular formula

C221H342N46O68

Sequence

YXQGTFTSDYSIXLDKKAQXAFIEYLLEGGPSSGAPPPS

Typical dose range

0.5–12 mg once weekly subcutaneous (Phase 2 titration; 2–8 mg most studied maintenance range)

Half-life

~6 days

Independent evidence

COAs for Retatrutide

494 third-party tests across 54 vendors. Each card links to the full report.

All 494 COAs for Retatrutide →
Measured purity 98.1%–100.0% across 295 COAs
Measured purity over time
✓ Vendor-published
99.81 %
Aug 2026
Kovera Labs

For

Retatrutide

by Reta One Labs· batch RT120826

COA on file
✓ Vendor-published
100.00 %
Aug 2026
ILS Laboratories

For

Retatrutide

by Sunrise Bioresearch· batch GLP320JUL26-01

COA on file
✓ Vendor-published
99.65 %
Aug 2026
Kovera Labs

For

Retatrutide

by Reta One Labs· batch RT150826

COA on file
✓ Vendor-published
99.78 %
Jul 2026
Kovera Labs

For

Retatrutide

by Reta One Labs· batch RT700726

COA on file
Aggregated · 3rd-party listing
99.94 %
Jul 2026
Testides

For

Retatrutide

by Longeva· batch B-2026-RETA-60-002

Aggregated · 3rd-party listing
99.95 %
Jul 2026
Accumark Labs

For

Retatrutide

by Peptide Crafters· batch PC-J3-RT60

Aggregated · 3rd-party listing
99.84 %
Jul 2026
Freedom Diagnostics Moderate

For

Retatrutide

by Peptide Plugs· batch 101-01-ZB

Aggregated · 3rd-party listing
99.99 %
Jul 2026
ILS Labs Strong

For

Retatrutide

by NG Peptide· batch RT20-09

Aggregated · 3rd-party listing
99.86 %
Jul 2026
ILS Labs Strong

For

Retatrutide

by Aspire Peptides· batch RT20-032026-1

Aggregated · 3rd-party listing
99.71 %
Jul 2026
ILS Labs Strong

For

Retatrutide

by Hydro Research Peptides· batch HR-2026-2836

Aggregated · 3rd-party listing
99.78 %
Jul 2026
ILS Labs Strong

For

Retatrutide

by Aspire Peptides· batch RT15-032026-1

Aggregated · 3rd-party listing
99.72 %
Jul 2026
ILS Labs Strong

For

Retatrutide

by Aspire Peptides· batch GLP-3R

Aggregated · 3rd-party listing
99.46 %
Jul 2026
Horizon Analytical

For

Retatrutide

by Blank Peptides· batch B-1784041-P

Aggregated · 3rd-party listing
98.08 %
Jul 2026
Chromate Moderate

For

Retatrutide

by Moglabs· batch RT103

Aggregated · 3rd-party listing
98.08 %
Jul 2026
Chromate Moderate

For

Retatrutide

by Arcane Peptides· batch RT103

✓ Vendor-published
98.08 %
Jul 2026
Chromate Moderate

For

Retatrutide

by Arcane Peptides· batch RT103

COA on file
✓ Vendor-published
98.08 %
Jul 2026
MogLabs.bio

For

Retatrutide

by Moglabs· batch RT103

COA on file
Aggregated · 3rd-party listing
99.28 %
Jul 2026
Janoshik Analytical Limited

For

Retatrutide

by EZ Peptides· batch EZP-3P1206222026-03

✓ Vendor-published
99.78 %
Jul 2026
Kovera Labs

For

Retatrutide

by Peptide Partners· batch RTT2613

COA on file
✓ Vendor-published
99.28 %
Jul 2026
Janoshik Analytical Limited

For

Retatrutide

by EZ Peptides· batch EZP-3P1206222026-03

COA on file
Aggregated · 3rd-party listing
99.81 %
Jul 2026
ILS Labs Strong

For

Retatrutide

by Virtus Peptides· batch RT30-655

Aggregated · 3rd-party listing
99.62 %
Jul 2026
ILS Labs Strong

For

Retatrutide

by Virtus Peptides· batch RT10-655

Aggregated · 3rd-party listing
98.71 %
Jul 2026
Janoshik Analytical Limited

For

Retatrutide

by Optima Supply· batch OS-2026-1258

Aggregated · 3rd-party listing
98.71 %
Jul 2026
Janoshik Analytical Limited

For

Retatrutide

by Hydro Research Peptides· batch HR-2026-2051

Research depth

23 citations indexed for Retatrutide

All research on Retatrutide →

case-report · 2026

Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis

Growing public interest in incretin-based therapies for weight loss has been accompanied by increasing availability of research peptides purchasable online. Products may be used without medical assessment or counselling regarding adverse effects, sick-day management or appropriate follow-up.

Study · 2026

Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes

Aims To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D).

animal · 2026

Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice

Chronic kidney disease is a major health burden. Given the therapeutic potential of GLP-1 receptor agonists (semaglutide, tirzepatide, and retatrutide) in diabetic nephropathy, we evaluated their anti-fibrotic and anti-inflammatory effects in non-diabetic renal fibrosis using HK-2 cells and murine UUO and aging models.

animal · 2026

Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats

Diabetes mellitus is associated with cognitive impairment and neurodegenerative changes, partly through hyperglycaemia-driven neuroinflammation and disrupted neuronal signalling.

review · 2026

Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Introduction It has been reported that glucagon-like peptide-1 (GLP-1) agonists or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists exert beneficial effects on blood pressure and lipid profile.

rct · 2026

Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial

Background Retatrutide is a GIP, GLP-1, and glucagon triple hormone receptor agonist, under clinical development for type 2 diabetes, obesity, and related complications.